Lexology August 29, 2024
Taylor Wessing

Alice Matthews and Adrian Toutoungi dig through the stand-out July 2024 biopharma deals. Neurodegenerative disease deals are resurgent, after a few months dominated by other therapeutic indications (and in the month that the CHMP gave a negative opinion for Biogen/Eisei’s Lequembi™). Other themes for the month included: (i) continued interest in discovery stage deals for antibody-drug conjugates (ADC), following on from our June 2024 update; and (ii) a cold wind blowing in the SHP2 inhibitor space; (iii) headwinds for AIDD-focused deals.

Deal of the month

  • Roche has invested an upfront payment of $50 million in upfront and near-term milestone payments for an exclusive license to a Sangamo Therapeutics’ proprietary zinc finger repressor directed at the tau gene (and at...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Partnerships, Pharma, Pharma / Biotech, Trends
Related Articles:
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
New AI model can estimate a person's true biological age from five drops of blood
Spotiphy AI Tool Enhances Spatial Transcriptomics for Precision Medicine
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
FDA Approves First Biosimilar to Omalizumab

Share This Article